Navigation Links
TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year
Date:6/25/2010

New CDC Guidelines Prefer Use of Blood Tests, including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations

Valencia, CA (PRWEB) June 25, 2010 -- The United States (U.S.) Centers for Disease Control and Prevention (CDC) issued new and important guidelines on the detection of Mycobacterium tuberculosis infections, the causative agent of tuberculosis (TB). In these landmark guidelines, CDC advises that Interferon Gamma Release Assay (IGRA) blood tests are now preferred over the 100+-year-old tuberculin skin test (TST) for diagnosing TB infection in certain populations, including people who typically do not return for the necessary reading of TST results, and those who have received Bacille Calmette-Guérin (BCG) as a vaccine or for cancer therapy. Typically the TST or IGRAs, such as QuantiFERON®-TB Gold (QFT), manufactured by Cellestis Limited, should be used as aids to diagnose infection with M. tuberculosis.

Developing countries are in a constant battle against the ravaging effects of the tuberculosis crisis. With global migration and the highly contagious nature of tuberculosis, the disease remains a significant threat to public health in the U.S. Settling into the lungs, the spine, the kidneys and the brain, tuberculosis can be fatal without proper treatment. The CDC estimates that up to 14 million people in the U.S. are TB infected and asymptomatic - with three-quarters remaining undiagnosed - and at risk of progressing to highly contagious TB disease.

For more information, please visit www.TackleTB.com.

TB disease can be prevented by treating the symptomless infection before disease strikes. Convenient and trustworthy testing for TB infection is vital in order to quickly identify people needing treatment and thereby preventing the spread of TB. QFT is sound, evidence-based technology that virtually eliminates false positive results and more definitively indicates when a patient is infected with the TB bacterium. For the uninfected individual, this spares the anxiety and concern that a positive TST result, which may often be falsely positive, may cause. A false-positive TB test usually leads to unwarranted medical consultations and often, unnecessary treatment. For those unfortunate enough to be infected, the higher accuracy of QFT (over TST) greatly increases the likelihood that their infection will be detected. Use of QFT provides significant risk reduction for the millions of health professionals, employees, patients, and individuals who may come in contact with TB in the course of their work.

About QuantiFERON-TB Gold (QFT)
QuantiFERON-TB Gold (QFT) is a simple blood test that accurately identifies people infected with Mycobacterium tuberculosis, the causative agent of Tuberculosis (TB). As a modern alternative to the 110 year old Tuberculin Skin Test (TST), also known as the Mantoux, QFT offers unmatched specificity, high sensitivity and simplicity. QFT enables focused TB therapy by providing clinicians with an accurate, reliable and convenient TB diagnostic tool. QFT is unaffected by previous BCG vaccination and most other environmental mycobacteria. Unlike the TST, it requires only one patient visit, is a controlled laboratory test and provides an objective, reproducible result that is unaffected by subjective interpretation. Results can be available within 24 hours.

QFT is available for use in all clinical settings in which TST is commonly used. Examples include contact tracing, regular employee testing, for example for health care workers, as well as screening programs for prisoners and immigrants. QFT's application offers distinct advantages over the TST in the screening of immunosuppressed patients prior to anti-TNF-alpha therapy initiation and in patients with HIV, cancer or organ transplants.

QFT is sold directly in the U.S. by Cellestis Inc; in Europe by Cellestis GmbH (Germany); and in Australia and Asia by Cellestis International Pty. Ltd. (Australia). QFT is also available through Cellestis Commercial Partners in Japan, Europe, the Middle East and other countries around the world.

Multimedia Release: Multimedia Content Attached

# # #

Read the full story at http://www.prweb.com/releases/2010/06/prweb4189974.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Many Supplements Said to Contain Toxins, Make False Health Claims
2. Osteoarthritis Claims Growing Number of Younger Victims
3. FDA to Take Up Major Enforcement Action Against Cosmetics Manufacturers With Illegal “Anti-Aging” Labeling Claims, According to FDAImports.com, LLC
4. Salt Lake City proclaims Molecular Imaging Days during SNMs Annual Meeting in June
5. BPA in Cans Poses Health Threat, Report Claims
6. False Claims Act Attorney Tim Terry to Address Arizona Chapter of the Association of Certified Fraud Examiners
7. Health Claims on Foods May Not Be Well-Grounded
8. Martin & Jones Announces Class Action Lawsuit Against Major Employer, Claims Thousands of Visiting Nurses Illegally Denied Overtime Pay
9. KEL Attorneys is Assisting Victims of the Deepwater Horizon Oil Spill by Filling Legal Claims on Their Behalf
10. Assessing the science behind health claims
11. Allsup Outlines Quick-Processing Methods for Social Security Disability Claims
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
TB Claims One Life Every 17 Seconds; Almost Two Million People Each Year 
(Date:3/24/2017)... ... 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce ... The clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... provide care from the clinic, which opened March 22, 2017. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the ... create a communications platform that positions them as the go-to thought leader in ... their online publication as an always-on, always-fresh news, views and advocacy engine, called ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... announced their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that ... 87th Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of Christian ... Bible teacher residing in North Carolina with his wife, Anna Marie. He and his ... six grandchildren. David is also the author of “Shadow and Substance.” , “Love, the ...
(Date:3/23/2017)... ... , ... The physicians of KSF Orthopaedic Center PA are proud to announce ... is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside ... patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... -- Executive Summary ... research (inputs from industry experts, companies, stakeholders) and ... analysis of global heart valve devices market on ... Procedure By Technique (Mechanical, Bioprosthetic, Transcatheter Aortic Valve ... Valvuloplasty, Transcatheter Mitral Valve Repair (TMVR)), By Region ...
(Date:3/23/2017)... SPRING, Md. , March 23, 2017  The ... to Bavencio (avelumab) for the treatment of adults and ... cell carcinoma (MCC), including those who have not received ... metastatic MCC, a rare, aggressive form of skin cancer. ... most common cancers, patients with a rare form called ...
(Date:3/23/2017)... and VANCOUVER, British Columbia ... SPHS ) (the "Company" or "Sophiris"), a ... treatment of urological diseases, today announced that data from ... the drug as a focal treatment for localized prostate ... 26, 2017 at the 32 nd Annual European ...
Breaking Medicine Technology: